Table 1.

The hepatitis C care cascade by specialty for patients with injecting-drug-use-related episodes, 2018–2021.

Specialty	Episodes (n = 1643)	Unique Patients (n = 1345)	Antibody Testing, n (% of Patients)	Antibody Positive, n (% of Total Antibody Testing)	RNA Testing, n (% of Antibody Positive)	RNA Positive, n (% of Total RNA Testing)
Hepatitis specialist	14 (0.9%)	12 (85.7%)	0 (0%; 0)	0 (0%)	0 (0%)	0 (0%)
Emergency	820 (49.9%)	694 (84.6%)	24 (3.5%)	14 (26.9%)	2 (14.3%)	3 (60%)
Surgical	121 (7.4%)	111 (91.7%)	5 (4.5%)	7 (50%)	0 (0%)	2 (50%)
General Medicine	371 (22.6%)	325 (87.6%)	14 (4.3%)	16 (41%)	2 (12.5%)	3 (37.5%)
Mental Health	103 (6.3%)	91 (88.3%)	8 (8.8%)	6 (54.5%)	1 (16.7%)	1 (100%)
Obstetrics and Gynecology	26 (1.6%)	24 (92.3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Other specialty medicine	188 (11.4%)	139 (73.9%)	6 (4.3%)	6 (28.6%)	1 (16.7%)	5 (83.3%)
Total	1643	1345	98 (7.3%)	38 (38.8%)	23 (60.5%)	22 (95.7%)